BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 25589151)

  • 21. [Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients].
    Sun B; Song ST; Jiang ZF; Wang T; Zhang SH; Meng XY; Li XB; Yu CZ; Wu SK
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):38-42. PubMed ID: 23648298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer.
    Chen S; Liu Y; Ouyang QW; Huang L; Luo RC; Shao ZM
    Ann Surg Oncol; 2015 Jan; 22(1):32-9. PubMed ID: 25012266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three-dimensional ultrasonography of the breast; An adequate replacement for MRI in neoadjuvant chemotherapy tumour response evaluation? - RESPONDER trial.
    van Egdom LSE; Lagendijk M; Heijkoop EHM; Koning AHJ; van Deurzen CHM; Jager A; van Lankeren W; Koppert LB
    Eur J Radiol; 2018 Jul; 104():94-100. PubMed ID: 29857873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy.
    Baron P; Beitsch P; Boselli D; Symanowski J; Pellicane JV; Beatty J; Richards P; Mislowsky A; Nash C; Lee LA; Murray M; de Snoo FA; Stork-Sloots L; Gittleman M; Akbari S; Whitworth P
    Ann Surg Oncol; 2016 May; 23(5):1522-9. PubMed ID: 26714960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting Post Neoadjuvant Axillary Response Using a Novel Convolutional Neural Network Algorithm.
    Ha R; Chang P; Karcich J; Mutasa S; Van Sant EP; Connolly E; Chin C; Taback B; Liu MZ; Jambawalikar S
    Ann Surg Oncol; 2018 Oct; 25(10):3037-3043. PubMed ID: 29978368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response.
    Fisher CS; Ma CX; Gillanders WE; Aft RL; Eberlein TJ; Gao F; Margenthaler JA
    Ann Surg Oncol; 2012 Jan; 19(1):253-8. PubMed ID: 21725686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
    Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing residual cancer cells using MRI and US after preoperative chemotherapy in primary breast cancer to omit surgery.
    Iwase M; Sawaki M; Hattori M; Yoshimura A; Ishiguro J; Kotani H; Gondo N; Adachi Y; Kataoka A; Onishi S; Sugino K; Iwata H
    Breast Cancer; 2018 Sep; 25(5):583-589. PubMed ID: 29619758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients.
    Livingston-Rosanoff D; Schumacher J; Vande Walle K; Stankowski-Drengler T; Greenberg CC; Neuman H; Wilke LG
    Clin Breast Cancer; 2019 Dec; 19(6):e741-e747. PubMed ID: 31300338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer.
    Guarneri V; Pecchi A; Piacentini F; Barbieri E; Dieci MV; Ficarra G; Tazzioli G; Frassoldati A; Battista R; Canossi B; Mauri C; D'Amico R; Conte P; Torricelli P
    Ann Surg Oncol; 2011 Aug; 18(8):2150-7. PubMed ID: 21301969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intraoperative Ultrasound-Guided Lumpectomy Versus Mammographic Wire Localization for Breast Cancer Patients After Neoadjuvant Treatment.
    Rubio IT; Esgueva-Colmenarejo A; Espinosa-Bravo M; Salazar JP; Miranda I; Peg V
    Ann Surg Oncol; 2016 Jan; 23(1):38-43. PubMed ID: 26514120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Chemotherapy-Induced Ovarian Dysfunction on Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Ahn SK; Lee HB; Han W; Moon HG; You JM; Kim J; Han SW; Im SA; Kim TY; Noh DY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S391-7. PubMed ID: 26275780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
    Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
    Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer.
    Lee SC; Grant E; Sheth P; Garcia AA; Desai B; Ji L; Groshen S; Hwang D; Yamashita M; Hovanessian-Larsen L
    J Ultrasound Med; 2017 May; 36(5):901-911. PubMed ID: 28150325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.
    Chen JH; Bahri S; Mehta RS; Kuzucan A; Yu HJ; Carpenter PM; Feig SA; Lin M; Hsiang DJ; Lane KT; Butler JA; Nalcioglu O; Su MY
    Radiology; 2011 Dec; 261(3):735-43. PubMed ID: 21878615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2-D and 3-D Ultrasound for Tumor Volume Analysis: A Prospective Study.
    González SJ; Mooney B; Lin HY; Zhao X; Kiluk JV; Khakpour N; Laronga C; Lee MC
    Ultrasound Med Biol; 2017 Apr; 43(4):775-781. PubMed ID: 28187928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy.
    De Los Santos J; Bernreuter W; Keene K; Krontiras H; Carpenter J; Bland K; Cantor A; Forero A
    Clin Breast Cancer; 2011 Oct; 11(5):312-9. PubMed ID: 21831721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy.
    Yang L; Zhong X; Pu T; Qiu Y; Ye F; Bu H
    World J Surg Oncol; 2018 Mar; 16(1):51. PubMed ID: 29514654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.